|
Poster number |
Title |
Submitting author |
City and Country |
|
189 |
AMAHRELIS : Adcetris maintenance after autologous stem cell transplantation in Hodgkin lymphoma : a real life study from SFGMTC and LYSA groups. |
Bénédicte Deau |
Paris, France |
|
190 |
Long-term follow-up and biomarker analyses of brentuximab vedotin and DHAP in relapsed/refractory Hodgkin lymphoma patients: the HOVON/LLPC Transplant Brave study. |
Julia Driessen |
Amsterdam, Netherlands |
|
191 |
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience |
Alice Morigi |
Bologna, Italy |
|
192 |
Camrelizumab Combined with GEMOX in Patients with Relapsed or Refractory Hodgkin Lymphoma |
Yan Xie |
Beijing, China |
|
193 |
Health-Related Quality of Life Among Patients With Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in a Phase 3 Study of Pembrolizumab Versus Brentuximab Vedotin |
Pier Luigi Zinzani |
Bologna, Italy |
|
194 |
Real world outcomes and responses to second-line therapy in relapsed/refractory Hodgkin lymphoma: a multicentre UK study |
Rohan Shotton |
Manchester, UK |
|
195 |
Clinical Outcomes of Relapsed Hodgkin Lymphoma Patients after Contemporary First-Line Treatment: Results from the German Hodgkin Study Group |
Paul Bröckelmann |
Cologne, Germany |
|
196 |
PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: long term follow up of the GATLA LH-05 trial |
Astrid Pavlovsky |
Buenos Aires, Argentina |
|
197 |
MODIFICATION OF ESCALATED BEACOPP WITH DACARBAZINE SUBSTITUTION REDUCES TOXICITY WHILE MAINTAINING EFFICACY FOR THE TREATMENT OF ADVANCED STAGE HODGKIN LYMPHOMA |
Anna Santarsieri |
Cambridge, UK |
|
198 |
Mature Results from a Phase II Trial of Brentuximab Vedotin plus Adriamycin and Dacarbazine Without Radiation in Non-bulky Limited Stage Classical Hodgkin Lymphoma |
Jeremy Abramson |
Boston, MA, USA |
|
199 |
Brentuximab vedotin as consolidation treatment in patients with stage I/II classical Hodgkin’s lymphoma and a positive FDG-PET after 2 cycles of ABVD: a LYSA phase 2 study. |
Thomas Gastinne |
Nantes, France |
|
200 |
Outcomes after initial refusal of curative treatment in patients with Hodgkin lymphoma in British Columbia |
Manik Chahal |
Vancouver, Canada |
|
201 |
Prognostic factors in elderly patients with classical Hodgkin Lymphoma - a joint analysis of two clinical databases |
Martin Fehr |
St. Gallen, Switzerland |
|
202 |
MTV, TLG and SUV max as promising parameters to predict early response in patients with HL treated with ABVD. A retrospective sub-analysis of the GATLA-LH-05 trial. |
Julieta Iorio |
Ciudad de Buenos Aires-Recoleta, Argentina |
|
203 |
Baseline Maximum Tumour Diameter Is Associated with Event-Free Survival for PET-Negative Patients with Limited-Stage Hodgkin Lymphoma: Analysis of the H10 and RAPID Trials |
Elizabeth Phillips |
Manchester, UK |
|
204 |
Sarcopenia is an independent prognostic factor in elderly male patients with classical Hodgkin Lymphoma: results from a multicenter experience |
Vittorio Zilioli |
Milan, Italy |
|
205 |
Gut microbiota role in response to checkpoint inhibitor treatment in patients with relapsed/refractory B-cell Hodgkin lymphoma: an interim analysis from MICRO-LINF study |
Beatrice Casadei |
Bologna, Italy |
|
206 |
Characterization of cancer associated fibroblasts in classical Hodgkin lymphoma |
Kristiina Karihtala |
Helsinki, Finland |
|
207 |
Tracking clonal hematopoiesis in patients with classical Hodgkin's lymphoma |
Andrea Marra |
Perugia, Italy |